Reverse transcription polymerase chain reaction (RT-PCR) was used to examine the expression of the cannabinoid CB1 receptor mRNA in post-mortem brain tissue obtained from normal subjects and patients dying with Parkinson’s disease. CB1 receptor mRNA was detected in striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus, substantia nigra) brain regions. In parkinsonian tissue the level of CB1 receptor mRNA was decreased in the caudate nucleus, anterior dorsal putamen and external segment of the globus pallidus, but remained unchanged in the other brain areas examined. These results show that CB1 receptor mRNA expression was altered in Parkinson’s disease (though the effects of drug treatment can not be ruled out) and indicate that cannabinoid CB1 receptor mRNA expression was affected by alterations in dopaminergic systems.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Received July 12, 2001; accepted June 23, 2003 Published online August 13, 2003
Rights and permissions
About this article
Cite this article
Hurley, M., Mash, D. & Jenner, P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm 110, 1279–1288 (2003). https://doi.org/10.1007/s00702-003-0033-7
- Keywords: Parkinson’s disease, cannabinoid CB1 receptor mRNA, basal ganglia, RT-PCR.